The unique economic conditions arising from Covid-19 and national restrictions have caused certain difficulties in applying the arm’s length principle for transfer pricing analysis. To pick up where we left off in our article Covid-19: transfer pricing impact, this one explores Guidance on the transfer pricing implications of Covid-19 the OECD published in late 2020.
The Guidance emphasises that transfer pricing analysis should continue to rely on the OECD’s Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations dated July 2017 even in the unique circumstances caused by Covid-19. The Guidance focuses on how the arm’s length principle and the Guidelines relate to issues that can arise or become aggravated in the context of Covid-19, rather than on drawing up any specialised guidance to go beyond the instructions and recommendations currently made in the Guidelines.
To mitigate the effects of Covid-19 on transfer pricing analysis, the Guidance looks at four key matters dealt with in separate chapters:
The Guidance emphasises that although the matters are explained as four separate topics, they can be mutually related and should therefore be considered together with the interpretations offered in the Guidelines.
Unprecedented changes to the economic environment following the outbreak of Covid-19 have created unique difficulties in performing a comparability analysis. The Guidance states that the pandemic can affect pricing between related and unrelated parties, as well as reducing the scope for relying on historical data. The Guidance looks at comparability analysis in a series of questions, the most important being set out below.
The Guidance says that any sort of publicly available information on how Covid-19 affects business, industry and controlled transactions deserves to be analysed with a company’s transfer pricing policy for 2020. The Guidance lists several sources of information that can be used in transfer pricing analysis, such as information on sales volumes, macroeconomic trends, additional or extraordinary costs, budgeted data against actual data etc.
The Guidance states that financial results a taxpayer would have achieved in a controlled transaction but did not because of Covid-19 provide useful information for determining how Covid-19 affects the financial results and transfer prices. It is important to note that when it comes to comparing budgeted data with actual data, we need to consider all economic factors affecting the financial results in order to measure the isolated effect of the pandemic.
The Guidance urges tax authorities to consider taking pragmatic approaches in dealing with the lack of reliable comparables in order to minimise disputes where taxpayers try to identify arm’s length prices in good faith, for example:
According to the Guidance a comparability analysis that is based only on information from the 2008–2009 global financial crisis would create significant comparability risks, given the unique and unprecedented nature of Covid-19. When it comes to selecting years suitable for a comparability analysis, we need to ensure that financials for years affected by the pandemic do not unduly distort the results of pre-pandemic or post-pandemic periods.
When preparing a comparability analysis and selecting companies with financial results for 2020, the taxpayer might have to revise the criteria applied in the benchmarking study. For example, the impact of national restrictions can cause significant differences between the profit indicators of companies operating in the same sector. When it comes to reflecting the impact of Covid‑19 and related restrictions, it might be necessary to revise and relax other comparability criteria in order to obtain credible data from the most comparable market (country).
In a benchmarking study, we should not be rejecting companies only because they reported losses in periods affected by Covid-19. If the benchmarking study finds that a company performs comparable functions and takes comparable risks there is no reason to exclude it from our selection.
We will be posting more on the remaining topics of Guidance on the transfer pricing implications of Covid-19.
If you have any comments on this article please email them to lv_mindlink@pwc.com
Ask questionWe use cookies to make our site work well for you and so we can continually improve it. The cookies that keep the site functioning are always on. We use analytics and marketing cookies to help us understand what content is of most interest and to personalise your user experience.
It’s your choice to accept these or not. You can either click the 'I accept all’ button below or use the switches to choose and save your choices.
For detailed information on how we use cookies and other tracking technologies, please visit our cookies information page.
These cookies are necessary for the website to operate. Our website cannot function without these cookies and they can only be disabled by changing your browser preferences.
These cookies allow us to measure and report on website activity by tracking page visits, visitor locations and how visitors move around the site. The information collected does not directly identify visitors. We drop these cookies and use Adobe to help us analyse the data.
These cookies help us provide you with personalised and relevant services or advertising, and track the effectiveness of our digital marketing activities.